Cargando…

A Novel ASCT2 Inhibitor, C118P, Blocks Glutamine Transport and Exhibits Antitumour Efficacy in Breast Cancer

SIMPLE SUMMARY: ASCT2 is an attractive tumour metabolism target based on its critical role in cancer cell growth. The potential mechanisms of microtubule protein inhibitor C118P in breast cancer remain unknown. Identification of the potential target of C118P is essential. We evaluated the inhibitory...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lyu, Xiao-Dan, Liu, Yang, Wang, Jia, Wei, Yuan-Cheng, Han, Yi, Li, Xue, Zhang, Qian, Liu, Zheng-Rui, Li, Zheng-Zheng, Jiang, Jing-Wei, Hu, Hao-Lin, Yuan, Sheng-Tao, Sun, Li
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10605716/ https://www.ncbi.nlm.nih.gov/pubmed/37894450 http://dx.doi.org/10.3390/cancers15205082

Ejemplares similares

Targeting of glutamine transporter ASCT2 and glutamine synthetase suppresses gastric cancer cell growth
por: Ye, Jianxin, et al.
Publicado: (2018)

Homology Modeling Informs Ligand Discovery for the Glutamine Transporter ASCT2
por: Garibsingh, Rachel-Ann A., et al.
Publicado: (2018)

Ag120-Mediated Inhibition of ASCT2-Dependent Glutamine Transport has an Anti-Tumor Effect on Colorectal Cancer Cells
por: Yu, Wei, et al.
Publicado: (2022)

ASCT2 overexpression is associated with poor survival of OSCC patients and ASCT2 knockdown inhibited growth of glutamine‐addicted OSCC cells
por: Luo, Yijun, et al.
Publicado: (2020)

Targeting ASCT2‐mediated glutamine uptake blocks prostate cancer growth and tumour development
por: Wang, Qian, et al.
Publicado: (2015)

Pharmacological Blockade of ASCT2-dependent Glutamine Transport Leads To Anti-tumor Efficacy in Preclinical Models
por: Schulte, Michael L., et al.
Publicado: (2018)

ASCT2 regulates glutamine uptake and cell growth in endometrial carcinoma
por: Marshall, A D, et al.
Publicado: (2017)

Epigenetic silencing of microRNA-137 enhances ASCT2 expression and tumor glutamine metabolism
por: Dong, J, et al.
Publicado: (2017)

Structural characterisation reveals insights into substrate recognition by the glutamine transporter ASCT2/SLC1A5
por: Scopelliti, Amanda J, et al.
Publicado: (2018)

NDRG2 ablation reprograms metastatic cancer cells towards glutamine dependence via the induction of ASCT2
por: Ding, Mingchao, et al.
Publicado: (2020)

Functional and Kinetic Comparison of Alanine Cysteine Serine Transporters ASCT1 and ASCT2
por: Wang, Jiali, et al.
Publicado: (2022)

Cryo-EM structures of the human glutamine transporter SLC1A5 (ASCT2) in the outward-facing conformation
por: Yu, Xiaodi, et al.
Publicado: (2019)

Inhibition of glucose metabolism prevents glycosylation of the glutamine transporter ASCT2 and promotes compensatory LAT1 upregulation in leukemia cells
por: Polet, Florence, et al.
Publicado: (2016)

Midazolam exhibits antitumour and enhances the efficiency of Anti-PD-1 immunotherapy in hepatocellular carcinoma
por: Kang, Junwei, et al.
Publicado: (2022)

ASCT2 (SLC1A5)-dependent glutamine uptake is involved in the progression of head and neck squamous cell carcinoma
por: Zhang, Ze, et al.
Publicado: (2019)

ASCT2 is the primary serine transporter in cancer cells
por: Conger, Kelly O., et al.
Publicado: (2023)

Mechano-boosting nanomedicine antitumour efficacy by blocking the reticuloendothelial system with stiff nanogels
por: Li, Zheng, et al.
Publicado: (2023)

Targeting ASCT2-mediated glutamine metabolism inhibits proliferation and promotes apoptosis of pancreatic cancer cells
por: Wang, Wenbin, et al.
Publicado: (2022)

The glutamine transporter ASCT2 (SLC1A5) promotes tumor growth independently of the amino acid transporter LAT1 (SLC7A5)
por: Cormerais, Yann, et al.
Publicado: (2018)

GLUT1 and ASCT2 as Predictors for Prognosis of Hepatocellular Carcinoma
por: Sun, Hong-Wei, et al.
Publicado: (2016)

Cys Site-Directed Mutagenesis of the Human SLC1A5 (ASCT2) Transporter: Structure/Function Relationships and Crucial Role of Cys467 for Redox Sensing and Glutamine Transport
por: Scalise, Mariafrancesca, et al.
Publicado: (2018)

Delta-Tocotrienol Modulates Glutamine Dependence by Inhibiting ASCT2 and LAT1 Transporters in Non-Small Cell Lung Cancer (NSCLC) Cells: A Metabolomic Approach
por: Rajasinghe, Lichchavi Dhananjaya, et al.
Publicado: (2019)

Isoliquiritigen Enhances the Antitumour Activity and Decreases the Genotoxic Effect of Cyclophosphamide
por: Zhao, Hong, et al.
Publicado: (2013)

Rethinking glutamine metabolism and the regulation of glutamine addiction by oncogenes in cancer
por: Ni, Rui, et al.
Publicado: (2023)

D-Serine Is a Substrate for Neutral Amino Acid Transporters ASCT1/SLC1A4 and ASCT2/SLC1A5, and Is Transported by Both Subtypes in Rat Hippocampal Astrocyte Cultures
por: Foster, Alan C., et al.
Publicado: (2016)

An Overview of Antitumour Activity of Polysaccharides
por: Jin, Hongzhen, et al.
Publicado: (2022)

ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer
por: van Geldermalsen, M, et al.
Publicado: (2016)

HSF1 Stimulates Glutamine Transport by Super-Enhancer-Driven lncRNA LINC00857 in Colorectal Cancer
por: Shen, Qi, et al.
Publicado: (2022)

Bicarbonate transport as regulator of antitumour immunity in pancreatic cancer
por: Kay, Emily J., et al.
Publicado: (2023)

Discovery of secondary sulphonamides as IDO1 inhibitors with potent antitumour effects in vivo
por: Ge, Shushan, et al.
Publicado: (2020)

O-GlcNAcylation Coordinates Glutaminolysis by Regulating the Stability and Membrane Trafficking of ASCT2 in Hepatic Stellate Cells
por: Wang, Feixia, et al.
Publicado: (2022)

A one-gate elevator mechanism for the human neutral amino acid transporter ASCT2
por: Garaeva, Alisa A., et al.
Publicado: (2019)

Cysteine 467 of the ASCT2 Amino Acid Transporter Is a Molecular Determinant of the Antiport Mechanism
por: Scalise, Mariafrancesca, et al.
Publicado: (2022)

Epigenetic therapy with chidamide alone or combined with 5-azacitidine exerts antitumour effects on acute myeloid leukaemia cells in vitro
por: Li, Zheng, et al.
Publicado: (2022)

Glutamine metabolism in cancers: Targeting the oxidative homeostasis
por: Gong, Tengfang, et al.
Publicado: (2022)

The Treatment of Multiple Myeloma Patients Not Eligible for Asct
por: Richardson, Paul, et al.
Publicado: (2010)

CAR-T cells targeting CD38 and LMP1 exhibit robust antitumour activity against NK/T cell lymphoma
por: Li, Hongwen, et al.
Publicado: (2023)

NIR-driven Smart Theranostic Nanomedicine for On-demand Drug Release and Synergistic Antitumour Therapy
por: Zhao, Pengfei, et al.
Publicado: (2015)

Antitumour Antibiotics
por: Fox, B. W.
Publicado: (1979)

Novel alanine serine cysteine transporter 2 (ASCT2) inhibitors based on sulfonamide and sulfonic acid ester scaffolds
por: Ndaru, Elias, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ege6ucpo7uvdgm847hgkcgcdka